Compare Biogen Inc (BIIB) vs CSX Corporation (CSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs CSX Corporation — how do they compare? Biogen Inc trades at $191.88 (market cap $28.34B), while CSX Corporation trades at $49.93 (market cap $92.24B). The key difference: CSX Corporation is far larger — about 3.3× Biogen Inc's market cap, and CSX Corporation pays a 1.13% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | CSX | |
|---|---|---|
Market Cap | $28.34B | $92.24B |
Sector | Health | Industrials |
52-Week High | $216.63 | $49.92 |
52-Week Low | $122.68 | $32.05 |
Enterprise Value | $30.62B | $110.47B |
Dividend Yield | — | 1.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
CSX trades at $49.64, up 0.47% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported mixed recent earnings, beating in Q1 2026 but missing in Q4 2025, with Q2 2026 results expected soon. Revenue has trended down from $14.9B in 2022 to $14.1B in 2025, though net margins remain above 20%. Strong cash flow from operations supports dividends, including a recent $0.14 payout.
Outlook is cautiously optimistic given analyst consensus favoring Buy ratings (56.52%) and a price target near $48.87. Risks include declining revenue, high debt levels, and valuation multiples above industry norms. Earnings growth and operational efficiency gains are key catalysts for upside, but macroeconomic pressures on freight demand pose headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →
